Teleallergy: Where Have We Been and Where Are We Going?

Allison Ramsey; Ann Chen Wu; Bruce G Bender; Jay Portnoy

doi:10.1016/j.jaip.2022.08.032

Teleallergy: Where Have We Been and Where Are We Going?

J Allergy Clin Immunol Pract. 2023 Jan;11(1):126-131. doi: 10.1016/j.jaip.2022.08.032. Epub 2022 Sep 3.

Authors

Allison Ramsey¹, Ann Chen Wu², Bruce G Bender³, Jay Portnoy⁴

Affiliations

¹ Rochester Regional Health, Rochester, NY. Electronic address: allison.ramsey@rochesterregional.org.
² Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass.
³ National Jewish Health, Denver, Colo.
⁴ Children's Mercy Hospital, Kansas City, Mo.

PMID: 36064184
DOI: 10.1016/j.jaip.2022.08.032

Abstract

Telemedicine uptake in allergy/immunology was slow before the coronavirus disease 2019 pandemic, but has accelerated since. This review examines where telemedicine has been in allergy/immunology and where it is headed in the future. Focus is placed on patient, physician, and health care professional satisfaction with telemedicine, capacity to expand access to allergy/immunology care, cost considerations, the regulatory environment, and future applications of telemedicine including adherence monitoring, wearable biosensors, artificial intelligence, and machine learning addressed.

Keywords: Access; Adherence monitoring; Healthcare provider satisfaction; Patient satisfaction; Teleallergy; Telehealth; Telemedicine.

Publication types

Review

MeSH terms

Artificial Intelligence
COVID-19* / epidemiology
Humans
Hypersensitivity* / diagnosis
Hypersensitivity* / epidemiology
Hypersensitivity* / therapy
Patient Satisfaction
Physicians*
Telemedicine*